Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
卵巢癌细胞外囊泡蛋白质组指纹图谱用于纳米工程微系统的早期检测
基本信息
- 批准号:10373086
- 负责人:
- 金额:$ 62.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAdvisory CommitteesAreaBRCA mutationsBenignBiological AssayBiological MarkersBiologyBiopsyBloodBlood CirculationBlood capillariesBlood specimenCA-125 AntigenCancer ControlCancer DiagnosticsCancer PatientCancer cell lineCarcinoma in SituCell LineClinicalClinical SensitivityColon CarcinomaCommunicationCompanionsDetectionDevelopmentDiagnosisDiagnostic SensitivityDiseaseDropsEarly DiagnosisEngineeringEpithelial ovarian cancerExcisionFingerprintGeneral PopulationGenerationsGoalsHumanImmune responseImmunoassayImmunoprecipitationInterventionLiquid substanceMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of cervix uteriMalignant neoplasm of ovaryMammalian OviductsMass Spectrum AnalysisMessenger RNAMethodsMicroRNAsMicrofluidicsNanochip Analytical DeviceNeoplasm Circulating CellsOperative Surgical ProceduresOutcomeOvarianOvaryPathway interactionsPatientsPatternPlasmaPlayPopulation ControlPrintingProteinsProteomicsPublic HealthReportingReproducibilityRiskRoleSamplingScreening for Ovarian CancerScreening for cancerSensitivity and SpecificitySerousSerum MarkersSignaling ProteinSolid NeoplasmSourceSpecificitySpecimenSymptomsTechnologyTestingTimeTissuesTrainingTubeTumor AntigensTumor MarkersTumor stageTumor-DerivedUltrasonographyUntranslated RNAValidationVesicleWomanbasebiomarker panelcancer diagnosiscandidate markerclinical diagnosisclinically translatablecostcurative treatmentsdetection assaydiagnostic platformdisorder riskearly detection biomarkerseffusionexosomeextracellular vesicleshigh risk populationimaging modalityinnovationliquid biopsymalignant breast neoplasmmicrochipmicrofluidic technologymicrosystemsmortalitymutation carriernanonanoengineeringnanomaterialsnanopatternneoplastic cellnovelnovel markerpatient prognosispre-clinicalpresymptomatic testingprevention serviceprotein biomarkersprotein profilingroutine screeningscreeningself assemblytooltreatment responsetumortumor progression
项目摘要
PROJECT SUMMARY
Ovarian cancer is a silent killer that strikes with few, if any, symptoms. By the time a woman knows she has it,
the cancer is often advanced and the outlook grim. However, if epithelial ovarian cancer is caught early the
prognosis for the patient is excellent. Developing non-invasive and highly specific blood-based tests for pre-
symptomatic screening and early detection of ovarian cancer is therefore crucial. This is especially essential
since obtaining a biopsy is difficult, costly, and sometimes not even an option. In addition, most blood biomarkers
to date lack the necessary sensitivity and specificity for early detection of this silent killer. A fundamental
challenge is the extremely low concentrations of circulating biomolecules released from the developing tumors
at pre-clinical stages which can be 10,000-fold lower than their clinically detectable levels. Therefore, there is a
pressing need to uncover novel biomarkers, apply new strategies, and develop robust technologies to propel the
advancement of cancer diagnostics, especially in a disease such as ovarian cancer. We have focused our efforts
on small extracellular vesicles (sEVs), primarily small and large exosomes derived from the endolysosomal
pathway, which play important roles in cellular communication, immune response, and cancer progression via
transfer of a selective repertoire of biomolecules. sEVs/exosome release is significantly increased in most
neoplastic cells, including ovarian cancer and occurs continuously at all stages of tumor development. Tumor-
derived sEVs accumulate in human blood and malignant effusions. These vesicles carry enriched subsets of
biomolecules mirroring the tumor cells of origin, such as signaling proteins, tumor antigens, and functional RNAs
(mRNA and miRNAs), which offer a new strategy to surmount the challenge in reliable detection of intrinsically
low-level serum markers during early malignant transformation. Thus, the constitutive release and enrichment
of certain tumor markers within sEVs present distinctive opportunities for early cancer diagnosis. We
hypothesize that circulating sEVs, much akin to circulating tumor cells but more robust due to their active release
and incredible stability in bodily fluids, represent a greater source for the discovery of exo-biomarkers for early
detection, potentially while still confined to the fallopian tube. In addition, sEVs can serve as a 'liquid biopsy’ to
assess benefits and treatment responses in real time in cancer patients. Our innovative application merges EV
biology with nano-material/microfluidic technology to develop an advanced microfluidic platform to capture and
detect ovarian cancer-derived sEVs with high specificity and sensitivity from the circulation. This approach will
integrate validated fallopian tube and ovarian cancer associated exo-protein biomarkers (SA1), which will be
applied to a second-generation nano-engineered EV analysis chip (SA2). These studies will be followed by
clinical validation using longitudinal samples collected from asymptomatic women who later develop epithelial
ovarian cancer (SA3). Our ultimate goal is to develop a reliable blood-based assay that, when used in
conjunction with current screening approaches will decrease the mortality from ovarian cancer.
项目摘要
卵巢癌是一个沉默的杀手,几乎没有任何症状。当一个女人知道她拥有它的时候,
癌症往往是晚期,前景黯淡。然而,如果上皮性卵巢癌早期发现,
患者预后良好。开发非侵入性和高度特异性的血液检测,
因此,对卵巢癌进行症状筛查和早期发现至关重要。这一点尤为重要
因为获得活组织检查是困难的、昂贵的,并且有时甚至不是选择。此外,大多数血液生物标志物
到目前为止,缺乏必要的敏感性和特异性来早期发现这种沉默的杀手。一项基本
挑战是从发展中的肿瘤释放的循环生物分子的浓度极低
在临床前阶段,其可能比其临床可检测水平低10,000倍。因此有
迫切需要发现新的生物标志物,应用新的策略,并开发强大的技术,以推动
癌症诊断的进步,特别是在卵巢癌等疾病中。我们集中精力
在小的细胞外囊泡(sEV)上,主要是来自内溶酶体的小的和大的外泌体,
在细胞通讯、免疫应答和癌症进展中发挥重要作用,
转移生物分子的选择性库。sEV/外泌体释放在大多数人中显著增加,
肿瘤细胞,包括卵巢癌,并在肿瘤发展的所有阶段连续发生。肿瘤-
衍生的sEV在人血液和恶性积液中积累。这些囊泡携带丰富的亚群
反映肿瘤细胞起源的生物分子,如信号蛋白、肿瘤抗原和功能性RNA
(mRNA和miRNAs),这提供了一种新的策略,以克服在可靠的检测固有的
低水平的血清标志物在早期恶性转化。因此,组成性释放和富集
sEV中某些肿瘤标志物的减少为早期癌症诊断提供了独特的机会。我们
假设循环sEV非常类似于循环肿瘤细胞,但由于其活性释放而更稳健,
以及体液中令人难以置信的稳定性,代表了早期发现外生物标志物的更大来源。
检测,潜在地同时仍然局限于输卵管。此外,sEV可以作为“液体活检”,
评估癌症患者的真实的时间获益和治疗反应。我们的创新应用融合了EV
生物学与纳米材料/微流体技术,以开发先进的微流体平台,
以高特异性和灵敏度从循环中检测卵巢癌来源的sEV。这种方法将
整合经验证的输卵管和卵巢癌相关外蛋白生物标志物(SA 1),这将是
应用于第二代纳米工程EV分析芯片(SA 2)。这些研究之后,
临床验证使用纵向样本收集无症状妇女谁后来发展上皮
卵巢癌(SA 3)。我们的最终目标是开发一种可靠的基于血液的检测方法,
结合目前的筛查方法将降低卵巢癌的死亡率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANDREW K. GODWIN其他文献
ANDREW K. GODWIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANDREW K. GODWIN', 18)}}的其他基金
The Kansas Institute for Precision Medicine : Zeiss Axioscan 7
堪萨斯精准医学研究所:Zeiss Axioscan 7
- 批准号:
10610667 - 财政年份:2022
- 资助金额:
$ 62.69万 - 项目类别:
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
卵巢癌细胞外囊泡蛋白质组指纹图谱用于纳米工程微系统的早期检测
- 批准号:
10526715 - 财政年份:2021
- 资助金额:
$ 62.69万 - 项目类别:
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
卵巢癌细胞外囊泡蛋白质组指纹图谱用于纳米工程微系统的早期检测
- 批准号:
10621734 - 财政年份:2021
- 资助金额:
$ 62.69万 - 项目类别:
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
卵巢癌细胞外囊泡蛋白质组指纹图谱用于纳米工程微系统的早期检测
- 批准号:
10199594 - 财政年份:2021
- 资助金额:
$ 62.69万 - 项目类别:
Integrated exosomes profiling for minimally invasive diagnosis and monitoring of cancer
用于癌症微创诊断和监测的综合外泌体分析
- 批准号:
10307656 - 财政年份:2021
- 资助金额:
$ 62.69万 - 项目类别:
Extracellular Vesicle Proteomic Fingerprinting of Ovarian Cancer for Early Detection with a Nanoengineered Microsystem
卵巢癌细胞外囊泡蛋白质组指纹图谱用于纳米工程微系统的早期检测
- 批准号:
10737826 - 财政年份:2021
- 资助金额:
$ 62.69万 - 项目类别:
The Kansas Institute for Precision Medicine: IsoPlexis IsoSpark
堪萨斯精准医学研究所:IsoPlexis IsoSpark
- 批准号:
10806784 - 财政年份:2019
- 资助金额:
$ 62.69万 - 项目类别:
Biobanking and Biomarker Validation (BBV) Core
生物样本库和生物标志物验证 (BBV) 核心
- 批准号:
10582682 - 财政年份:2019
- 资助金额:
$ 62.69万 - 项目类别:
相似海外基金
Toward a Political Theory of Bioethics: Participation, Representation, and Deliberation on Federal Bioethics Advisory Committees
迈向生命伦理学的政治理论:联邦生命伦理学咨询委员会的参与、代表和审议
- 批准号:
0451289 - 财政年份:2005
- 资助金额:
$ 62.69万 - 项目类别:
Standard Grant